David Papermaster
Medical · Waukesha, WINPI 1225023708
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,531 of the $3,378 with a category attached, or 74.9%. 35 manufacturers reported payments, led by Astellas Pharma US Inc at 36.8% of the total. Among medical clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $30.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Procept Biorobotics Corporation$258
- Johnson & Johnson$163
- Halozyme Inc$141
- Merck$140
- Amgen$140
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$171%
- Food & beverage$2,53175%
- Education$83025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 32 | $1,243 |
| Procept Biorobotics Corporation | 2 | $258 |
| Johnson & Johnson | 3 | $163 |
| Halozyme Inc | 2 | $141 |
| Merck | 5 | $140 |
| Amgen | 3 | $140 |
| AbbVie(2 entities) | 6 | $125 |
| Urogen Pharma, Inc. | 6 | $110 |
| Bayer | 1 | $102 |
| Antares Pharma, Inc. | 5 | $89 |
| 180 Medical, Inc. | 4 | $83 |
| Myovant Sciences Inc. | 4 | $81 |
| Coloplast | 4 | $71 |
| Rochester Medical Corporation | 2 | $65 |
| AstraZeneca | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Clarus Therapeutics Inc. | 4 | $45 |
| Olympus America Inc. | 2 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Progenics Pharmaceuticals, Inc. | 2 | $32 |
| Boston Scientific | 1 | $31 |
| Foundation Medicine, Inc. | 2 | $25 |
| BD | 1 | $24 |
| Urovant Sciences Inc | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Convatec Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Endo USA, Inc. | 1 | $17 |
| Profound Medical Corp. | 1 | $16 |
| Telix Pharmaceuticals | 1 | $15 |
| Mission Pharmacal Company | 1 | $15 |
| Teleflex LLC | 1 | $12 |
| Axonics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,378 in reported general payments places this provider in the 95th percentile of 247 medical providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 108 | $88,324 |
| GemtesaVibegron | 95 | $64,618 |
| Testosterone | 57 | $8,380 |
| Tamsulosin Hcl | 552 | $6,077 |
| Dutasteride | 48 | $2,393 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 99 | $2,161 |
| Testosterone Cypionate | 40 | $1,921 |
| Solifenacin Succinate | 34 | $1,434 |
| Trospium Chloride | 31 | $1,193 |
| Oxybutynin Chloride ErOxybutynin Chloride | 65 | $1,157 |
| Finasteride | 85 | $1,145 |
| Methenamine Hippurate | 18 | $930 |
| Acetic Acid | 47 | $870 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $467 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,243 | $88,324108 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $61 | $64,61895 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 medical providers in Wisconsin.
Other medical in Waukesha
- Rebecca BlankOnalaska$31K
- Amanda BreuerMadison$28K
- Anna BakerMilwaukee$26K
- Amber EssenmacherMilwaukee$21K
- Andrea MattisonKenosha$14K
- Tina SchnellJanesville$8K
- Savannah MatheMilwaukee$6K
- Patrick DrechslerWausau$5K
- Andrea GilbertsonMadison$4K
- Irum ZiauddinMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.